What's Happening?
Bayer's drug Kerendia (finerenone) has received an expanded label from the U.S. Food and Drug Administration (FDA) to include the treatment of chronic kidney disease (CKD) associated with type 1 diabetes (T1D). This marks the first new therapy for these
patients in approximately 30 years. Kerendia, a mineralocorticoid receptor antagonist (MRA), was previously approved for CKD in patients with type 2 diabetes (T2D) and heart failure. The new indication is supported by findings from the phase 3 FINE-ONE study. This 242-subject trial, published in the New England Journal of Medicine, demonstrated that adding Kerendia to standard care for T1D and CKD patients led to a significantly greater decrease in the urinary albumin-to-creatinine ratio (UACR), a biomarker for kidney damage, by 25% from baseline over six months. The study also showed an improvement in the estimated glomerular filtration rate (EGFR), a measure of kidney function.
Why It's Important?
This expanded FDA approval for Kerendia is significant for the approximately 30% of individuals with type 1 diabetes in the U.S. who eventually develop chronic kidney disease. CKD in T1D patients increases their risk of kidney failure and cardiovascular events, representing a substantial unmet medical need. The introduction of Kerendia offers a new treatment option that could potentially slow the progression of kidney disease in this vulnerable population, improving their long-term health outcomes and quality of life. For Bayer, this broader use for Kerendia is expected to provide additional momentum to the product, which already saw a 75% increase in sales in the first half of the year. The company is relying on Kerendia and other new products to offset declining sales from its anticoagulant Xarelto and competitive pressures on eye drug Eylea, with an official peak annual sales estimate for finerenone across all indications exceeding €3 billion.
What's Next?
Bayer is actively pursuing further label extensions for Kerendia, including its use in non-diabetic patients with CKD, based on the results of the FIND-CKD study. The FIND-CKD study met its primary goal by demonstrating that finerenone significantly slowed the annual rate of decline in EGFR compared to placebo when added to standard-of-care treatment for patients with CKD associated with high blood pressure and other conditions. If successful, this could further broaden Kerendia's market reach and impact. The company will continue to monitor the drug's performance and market adoption in the newly approved T1D-associated CKD indication. Healthcare providers will begin integrating this new treatment option into their management strategies for T1D patients with CKD, potentially leading to improved patient care and reduced disease burden.
Beyond the Headlines
The approval of Kerendia for T1D-associated CKD highlights a broader trend in pharmaceutical development towards more targeted therapies for specific patient populations within chronic diseases. The long-standing lack of new treatments for this condition underscores the challenges and complexities of drug development for chronic diseases with diverse etiologies. This development could also stimulate further research into the underlying mechanisms of CKD in T1D and the potential for other novel therapeutic approaches. Furthermore, the success of Kerendia in expanding its indications could influence future regulatory pathways for drugs targeting similar chronic conditions, emphasizing the importance of robust clinical trial data demonstrating efficacy and safety in specific patient subgroups. The economic implications for healthcare systems will also be a key consideration, balancing the cost of innovative therapies with the long-term benefits of preventing kidney failure and cardiovascular complications.
